Bravenboer Nathalie, Holzmann Paulien J, ter Maaten Jan C, Stuurman Lotte M, Roos Jan C, Lips Paul
Department of Endocrinology, VU University Medical Center, Amsterdam, The Netherlands.
J Bone Miner Res. 2005 Oct;20(10):1778-84. doi: 10.1359/JBMR.050613. Epub 2005 Jun 26.
Long-term GH treatment in GH-deficient men resulted in a continuous increase in bone turnover as shown by histomorphometry. BMD continuously increased in all regions of interest, but more in the regions with predominantly cortical bone.
Adults with growth hormone (GH) deficiency have reduced rates of bone turnover and subnormal BMD. GH treatment is effective in enhancing bone turnover as shown by biochemical markers and bone histomorphometric studies. However, it is uncertain whether long-term treatment will result in higher bone mass. In this study, we present BMD and histomorphometric data on 5 years of GH treatment in GH-deficient men.
Thirty-eight adult men with childhood onset GH deficiency (20-35 years) were included in the study. Twenty-six of these had multiple pituitary hormone deficiencies and were on stable conventional hormone replacement. BMC (total body) and BMD (lumbar spine and hip) were measured before and after 1, 2, 3, 4, and 5 years of treatment. BMD in various regions of the total body was calculated by computer software (head, trunk, arms, and legs). Transiliac bone biopsies were obtained before and after 1 and 5 years of GH treatment.
Total body BMC increased 18% after 5 years of treatment. This increase was observed in all regions of interest: head, 13.7%; trunk, 27.8%; arms, 24.4%; legs, 13.8%. BMD also increased in all separately measured regions: lumbar spine, 9%; femoral neck, 11%; femoral trochanter, 16%. Lumbar spine area significantly increased (p=0.0002). Histomorphometric data showed increased osteoid surface (p<0.02), osteoid volume (p<0.01), and activation frequency (p<0.006), but trabecular bone volume did not increase significantly. Qualitative assessment of the cortical bone showed endosteal and periosteal bone formation.
In conclusion, GH considerably increases BMC after long-term treatment. The combination of BMD and histomorphometric data suggests that GH has a greater effect on cortical than on trabecular bone.
生长激素缺乏男性的长期生长激素治疗导致骨转换持续增加,组织形态计量学显示了这一点。所有感兴趣区域的骨密度持续增加,但在以皮质骨为主的区域增加得更多。
成年生长激素(GH)缺乏患者的骨转换率降低且骨密度低于正常水平。生化标志物和骨组织形态计量学研究表明,生长激素治疗可有效提高骨转换。然而,长期治疗是否会导致更高的骨量尚不确定。在本研究中,我们展示了生长激素缺乏男性接受5年生长激素治疗后的骨密度和组织形态计量学数据。
38名童年起病的成年生长激素缺乏男性(20 - 35岁)纳入本研究。其中26人存在多种垂体激素缺乏,且接受稳定的传统激素替代治疗。在治疗1、2、3、4和5年后测量全身骨矿含量(BMC)以及腰椎和髋部的骨密度(BMD)。通过计算机软件计算全身各个区域的骨密度(头部、躯干、手臂和腿部)。在生长激素治疗1年和5年后获取双侧髂骨活检样本。
治疗5年后全身骨矿含量增加了18%。在所有感兴趣区域均观察到这种增加:头部,13.7%;躯干,27.8%;手臂,24.4%;腿部,13.8%。所有单独测量区域的骨密度也增加了:腰椎,9%;股骨颈,11%;股骨大转子,16%。腰椎面积显著增加(p = 0.0002)。组织形态计量学数据显示类骨质表面增加(p < 0.02)、类骨质体积增加(p < 0.01)以及激活频率增加(p < 0.006),但小梁骨体积未显著增加。对皮质骨的定性评估显示有骨内膜和骨膜骨形成。
总之,长期治疗后生长激素可显著增加骨矿含量。骨密度和组织形态计量学数据相结合表明,生长激素对皮质骨的作用大于对小梁骨的作用。